Andrea Necchi
Ospedale San Raffaele · IRCCS San Raffaele · IRCCS San Raffaele Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrea Necchi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05535218 · Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder CancerClaudia Guerrieri · active not recruiting · Muscle-invasive Urothelial Carcinoma of the Bladder · principal investigator
- Ph2NCT05226117 · Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder CancerIRCCS San Raffaele · completed · Urothelial Carcinoma · principal investigator
- Ph2NCT04294277 · Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical SurgeryEuropean Association of Urology Research Foundation · terminated · Urothelial Cancer · principal investigator
- Ph2NCT03832673 · Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyFondazione IRCCS Istituto Nazionale dei Tumori, Milano · withdrawn · Muscle-invasive Bladder Cancer · principal investigator
- Ph2NCT03081923 · Durvalumab Alone or With Tremelimumab in Refractory Germ Cell TumorsFondazione IRCCS Istituto Nazionale dei Tumori, Milano · terminated · Germ Cell Tumor · principal investigator
- Ph2NCT02161692 · Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell TumorsFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Testicular Neoplasms, Germ Cell Tumors · principal investigator
- Ph2NCT02109328 · Alisertib in Chemotherapy-pretreated Urothelial CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Bladder Cancer, Transitional Cell Carcinoma · principal investigator
- Ph2NCT01851200 · Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsFondazione Michelangelo · completed · Germ Cell Cancer · principal investigator
- Ph2NCT01728233 · Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Penile Neoplasms, Carcinoma, Squamous Cell · principal investigator
- Ph2NCT01620970 · PF-03446962 in Relapsed or Refractory Urothelial CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Transitional Cell Carcinoma of Bladder · principal investigator
- Ph2NCT01031875 · Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to TreatmentFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer · unknown
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:05 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- 2,988 citationsRCR 94.8
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.N Engl J Med · 20172,822 citationsRCR 93.2
- 1,818 citationsRCR 57.2
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.Lancet Oncol · 20171,342 citationsRCR 42.4
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 20191,078 citationsRCR 40.4
- 607 citationsRCR 19.0
- Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.N Engl J Med · 2023459 citationsRCR 38.4
- 415 citationsRCR 15.5
- 403 citationsRCR 13.5
- 274 citationsRCR 10.9